MedPath

Effect of Nutrition Supplementation Combined With Resistance Exercise in Elderly With Sarcopenia.

Not Applicable
Completed
Conditions
Sarcopenia
Interventions
Dietary Supplement: milk supplement
Dietary Supplement: soy milk supplement
Behavioral: resistance exercise
Registration Number
NCT05035121
Lead Sponsor
Taipei Medical University
Brief Summary

The purpose of this study was determine whether milk or soy milk supplements combined with resistance exercise improved sarcopenia in the elderly. This study was randomized controlled trail that recruited elderly people ≧65 years old with sarcopenia in the nursing home of Taipei Veterans General Hospital Su-Ao and Yuanshan Branch from June 2017 to December, 2017. The participants were divided into three groups, such as control, milk supplement and soy milk supplement. The milk and soy milk groups provided 200 mL milk or soy milk two times per day. Moreover, all participants joined the resistance exercise training program, three times per week (30 min/time). After 12 weeks, the anthropometry, sarcopenia index, blood biochemical index, nutrition status index, inflammation index, insulin resistance index, and dietary intake were measured.

Detailed Description

The anthropometry data included body weight and body fat. The sarcopenia index included appendicular skeletal muscle mass index, calf circumferences, hand grip and gait speed. Moreover, blood biochemical index (liver function as ALT, kidney function as creatinine), nutrition status index (prealbumin, 25-hydroxyvitamin D) were also analyzed. The blood hsCRP level was as inflammation index and insulin resistance index included fasting blood sugar, insulin, HbA1c and HOMA-IR. The daily dietary intake were also recorded.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Age ≧ 65 years old
  • No allergies to milk and soy milk
  • Sarcopenia cases (AWGS)
  • Active ability
Exclusion Criteria
  • End-of-life patient or estimated death within six months
  • Last stage of cancer
  • Chronic kidney disease stage 4

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
milk supplementmilk supplementThe milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
milk supplementresistance exerciseThe milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
soy milk supplementsoy milk supplementThe soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
controlresistance exerciseThe participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
soy milk supplementresistance exerciseThe soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
Primary Outcome Measures
NameTimeMethod
height in metersbaseline

Height was measured by height meter

Change from baseline appendicular skeletal muscle mass index at 12 weeks12 weeks

The appendicular skeletal muscle mass muscle mass and height was combined to report appendicular skeletal muscle mass index in kg/m\^2.

Change from baseline hand grip at 12 weeks12 weeks

The muscle strength was evaluated with the hand-grip strength (kg) using a Smedley dynamometer (TTM-YD, Tsutsumi Industries, Tokyo, Japan)

appendicular skeletal muscle mass in kilogramsbaseline

The appendicular skeletal muscle mass was evaluated by bioelectrical impedance (BIA) analysis (Inbody S10, Inbody Inc., Seoul, South Korea)

Change from baseline appendicular skeletal muscle mass at 6 weeks6 weeks

The appendicular skeletal muscle mass was evaluated by bioelectrical impedance (BIA) analysis (Inbody S10, Inbody Inc., Seoul, South Korea)

Change from baseline appendicular skeletal muscle mass at 12 weeks12 weeks

The appendicular skeletal muscle mass was evaluated by bioelectrical impedance (BIA) analysis (Inbody S10, Inbody Inc., Seoul, South Korea)

Change baseline weeks height at 6 weeks6 weeks

Height was measured by height meter

Change from baseline height at 12 weeks12 weeks

Height was measured by height meter

appendicular skeletal muscle mass index in kg/m^2baseline

The appendicular skeletal muscle mass muscle mass and height was combined to report appendicular skeletal muscle mass index in kg/m\^2.

Change from baseline appendicular skeletal muscle mass index at 6 weeks6 weeks

The appendicular skeletal muscle mass muscle mass and height was combined to report appendicular skeletal muscle mass index in kg/m\^2.

calf circumferences in centimeterbaseline

calf circumferences (cm) was measured by using a measuring tape to go around the thickest point of the calf and stick tightly without squeezing the skin.

Change from baseline hand grip at 6 weeks6 weeks

The muscle strength was evaluated with the hand-grip strength (kg) using a Smedley dynamometer (TTM-YD, Tsutsumi Industries, Tokyo, Japan)

Change from baseline calf circumferences at 6 weeks6 weeks

calf circumferences (cm) was measured by using a measuring tape to go around the thickest point of the calf and stick tightly without squeezing the skin.

Change from baseline calf circumferences at 12 weeks12 weeks

calf circumferences (cm) was measured by using a measuring tape to go around the thickest point of the calf and stick tightly without squeezing the skin.

Change from baseline gait speed at 6 weeks6 weeks

The gait speed test was performed by recording the average time of walking 6 meters and representing with the distance (m) per second.

hand grip in kilogramsbaseline

The muscle strength was evaluated with the hand-grip strength (kg) using a Smedley dynamometer (TTM-YD, Tsutsumi Industries, Tokyo, Japan)

gait speed in meter per secondbaseline

The gait speed test was performed by recording the average time of walking 6 meters and representing with the distance (m) per second.

Change from baseline gait speed at 12 weeks12 weeks

The gait speed test was performed by recording the average time of walking 6 meters and representing with the distance (m) per second.

Secondary Outcome Measures
NameTimeMethod
Homeostasis model assessment-insulin resistance index (HOMA-IR)baseline

HOMA-IR was calculated according to the formula: fasting insulin (μU/mL) x fasting glucose (mmol/L)/22.5

Change from baseline blood alanine transaminase activity at 12 weeks12 weeks

The blood alanine transaminase (ALT) activity in U/L was measured as liver function index by automated clinical chemistry analyzer.

Change from baseline blood creatinine level at 12 weeks12 weeks

The blood creatinine level was measured as kidney function by automated clinical chemistry analyzer.

blood prealbumin level in mg/dLbaseline

The blood prealbumin level in mg/dL as the index of nutritional status were measured by automated clinical chemistry analyzer.

blood alanine transaminase activity in U/Lbaseline

The blood alanine transaminase (ALT) activity in U/L was measured as liver function index by automated clinical chemistry analyzer.

Change from baseline blood prealbumin level at 12 weeks12 weeks

The blood prealbumin level in mg/dL as the index of nutritional status were measured by automated clinical chemistry analyzer.

blood 25-hydroxyvitamin D level in ng/mLbaseline

The blood 25-hydroxyvitamin D level in ng/mL as the index of nutritional status were measured by automated clinical chemistry analyzer.

Change from baseline blood 25-hydroxyvitamin D level at 12 weeks12 weeks

The blood 25-hydroxyvitamin D level in ng/mL as the index of nutritional status were measured by automated clinical chemistry analyzer.

High sensitive C-reactive protein in mg/dLbaseline

High sensitive C-reactive protein (hsCRP) as the inflammatory indicator were measured by automated clinical chemistry analyzer.

blood creatinine level in mg/dLbaseline

The blood creatinine level was measured as kidney function by automated clinical chemistry analyzer.

blood fasting blood sugar in mg/dLbaseline

The blood fasting blood sugar level in mg/dL as the insulin resistance index was measured by automated clinical chemistry analyzer.

Change from baseline blood fasting blood sugar at 12 weeks12 weeks

The blood fasting blood sugar level in mg/dL as the insulin resistance index was measured by automated clinical chemistry analyzer.

blood insulin level in milli-international unit/Lbaseline

The blood insulin level in milli-international unit/L as the insulin resistance index was measured by commercial kits.

Change from baseline blood insulin level at 12 weeks12 weeks

The blood insulin level in milli-international unit/L as the insulin resistance index was measured by commercial kits.

blood HbA1c in percentagebaseline

The blood HbA1c in percentage as the insulin resistance index was measured by automated clinical chemistry analyzer.

Change from baseline blood HbA1c at 12 weeks12 weeks

The blood HbA1c in percentage as the insulin resistance index was measured by automated clinical chemistry analyzer.

Change from baseline High sensitive C-reactive protein at 12 weeks12 weeks

High sensitive C-reactive protein (hsCRP) as the inflammatory indicator were measured by automated clinical chemistry analyzer.

Change from baseline homeostasis model assessment-insulin resistance index (HOMA-IR) at 12 weeks12 weeks

HOMA-IR was calculated according to the formula: fasting insulin (μU/mL) x fasting glucose (mmol/L)/22.5

blood insulin-like growth factor 1 in mg/dLbaseline

The blood insulin-like growth factor 1 (IGF-1) level considered to be related with the protein synthesis in muscle was measured by chemiluminescence immunoassay.

Change from baseline blood insulin-like growth factor 1 at 12 weeks12 weeks

The blood insulin-like growth factor 1 (IGF-1) level considered to be related with the protein synthesis in muscle was measured by chemiluminescence immunoassay.

Trial Locations

Locations (1)

Taipei Medical University

🇨🇳

New Taipei City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath